Related Experiment Video
Updated: Jul 16, 2026
Tissue Triage and Freezing for Models of Skeletal Muscle Disease
Published on: July 15, 2014
The therapy of congenital myasthenic syndromes
1Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA. age@mayo.edu
Abstract:
Congenital myasthenic syndromes (CMSs) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more mechanisms. Specific diagnosis of a CMS is important as some medications that benefit one type of CMS can be detrimental in another type. In some CMSs, strong clinical clues point to a specific diagnosis. In other CMSs, morphologic and in vitro electrophysiologic studies of the neuromuscular junction, determination of the number of acetylcholine receptors (AchRs) per junction, and molecular genetic studies may be required for a specific diagnosis. Strategies for therapy are based on whether a given CMS decreases or increases the synaptic response to acetylcholine (ACh). Cholinesterase inhibitors that increase the synaptic response to ACh and 3,4-diaminopyridine, which increases ACh release, are useful when the synaptic response to ACh is attenuated. Long-lived open-channel blockers of the AChR, quinidine, and fluoxetine, are useful when the synaptic response is increased by abnormally prolonged opening episodes of the AChR channel. Ephedrine has beneficial effects in some CMSs but its mechanism of action is not understood.
Insights
Congenital myasthenic syndromes (CMSs) are neuromuscular disorders requiring precise diagnosis for effective treatment. Therapies vary based on how CMS affects acetylcholine response, with specific medications beneficial for certain types but harmful for others.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Congenital myasthenic syndromes (CMSs) represent a group of heterogeneous genetic disorders affecting neuromuscular transmission.
- Impaired neuromuscular transmission in CMS compromises the safety margin, leading to muscle weakness.
Purpose of the Study:
- To highlight the importance of specific diagnosis in managing congenital myasthenic syndromes.
- To outline diagnostic approaches and therapeutic strategies tailored to CMS subtypes.
Main Methods:
- Clinical assessment for diagnostic clues.
- Morphologic and electrophysiologic studies of the neuromuscular junction.
- Quantification of acetylcholine receptors (AchRs) per junction.
- Molecular genetic studies for definitive diagnosis.
Main Results:
- Therapeutic strategies depend on whether CMS decreases or increases the synaptic response to acetylcholine (ACh).
- Cholinesterase inhibitors and 3,4-diaminopyridine benefit CMS with attenuated ACh response.
- AChR channel blockers like quinidine and fluoxetine are useful for CMS with increased ACh response due to prolonged channel opening.
Conclusions:
- Accurate diagnosis of CMS is crucial as treatments can be detrimental if misapplied.
- Tailored therapeutic approaches based on the specific CMS mechanism optimize patient outcomes.
- Further research is needed to elucidate the mechanism of action for drugs like ephedrine in certain CMS cases.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myasthenia Gravis ll: Pathophysiology
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...